The Pelthos Therapeutics Inc. (PTHS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nevada-incorporated biopharmaceutical company listed on the NYSE American, Pelthos files a range of documents with the U.S. Securities and Exchange Commission that describe its business, governance, and financial obligations.
Key filings include Form 8-K current reports, where Pelthos discloses material events such as financing transactions, product acquisitions, and governance changes. Recent 8-K filings describe a senior secured term loan facility with Horizon Technology Finance Corporation intended to support commercialization of ZELSUVMI and the launches of Xepi and Xeglyze, an asset purchase agreement for the Xeglyze head lice treatment, and a securities purchase agreement for senior secured convertible notes used to fund the acquisition and planned relaunch of Xepi and to accelerate ZELSUVMI commercialization.
Other 8-K items and the company’s definitive proxy statement on Schedule 14A provide detail on board composition, director compensation policies, annual meeting proposals, and shareholder voting results. These documents outline Pelthos’ governance structure, committee responsibilities, and the terms under which directors and executives are compensated and indemnified.
On Stock Titan, investors can review Pelthos’ periodic reports (such as Forms 10-K and 10-Q when filed) for information on revenue from ZELSUVMI, operating expenses, cash position, and risk factors related to its commercial dermatology portfolio and financing arrangements. Form 4 and related insider transaction reports, when available, show equity dealings by directors and officers, offering additional insight into insider alignment.
AI-driven summaries on this page highlight the most important points from lengthy filings, such as covenants in loan agreements, conversion terms in convertible notes, and implications of mergers and name changes. Real-time updates from EDGAR ensure that new Pelthos filings—whether related to financings, acquisitions, or governance—are quickly reflected, while the AI layer helps users understand how each document fits into the company’s broader strategy around ZELSUVMI, Xepi, and Xeglyze.
Pelthos Therapeutics Inc. director Peter Greenleaf sold 797 shares of common stock at $21.17 per share on October 2, 2026, leaving him with 23,087 directly held shares. The sale was made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the issuer.
Ezra M. Friedberg, a director of Pelthos Therapeutics Inc. (PTHS), sold 558 shares of common stock on October 2, 2026, at $20.7169 per share under a Rule 10b5-1 plan adopted December 16, 2025, to satisfy estimated tax obligations tied to vesting of issuer-granted restricted stock units. He directly held 80,484 shares afterward.
Matthew Pauls, a director of Pelthos Therapeutics Inc. (PTHS), sold 786 shares of common stock on October 2, 2026, at $21 per share. He directly held 13,578 shares after the transaction. The sale was made under a Rule 10b5-1 plan adopted December 16, 2025, to satisfy estimated tax obligations connected with vesting of restricted stock units granted by the company.
Pelthos Therapeutics Inc. (PTHS) stockholders approved the 2026 Equity Incentive Plan at the September 29, 2026 annual meeting, replacing the 2023 Equity Incentive Plan, as amended and restated. The new plan became effective immediately upon stockholder approval.
Stockholders also elected eight director nominees to serve until the 2027 annual meeting or until their successors are elected and qualified, or their earlier resignation or removal. A total of 3,396,094 votes, representing 70.0% of eligible voting power, were present. The plan received 2,698,543 votes for, 187,365 against, 13 abstentions and 510,173 broker non-votes.
Pelthos Therapeutics Inc. (PTHS) is asking shareholders to vote at a virtual annual meeting on September 29, 2026. Shareholders of record as of August 4, 2026 may attend and vote online.
The agenda includes electing eight directors, ratifying Grant Thornton LLP as independent auditor for 2026, and approving the new 2026 Equity Incentive Plan. Common stock (3,828,469 shares) has one vote per share; Series A Preferred Stock (52,128 shares) votes on an as-converted basis at a $1.255 voting conversion price, subject to per‑holder caps that limit voting power (including 49.9% for Ligand Pharmaceuticals).
Ligand beneficially owns 2,321,363 common shares (49.9%) and is a key commercial and financing counterparty through royalty, licensing, and preferred stock and convertible note investments. As of December 31, 2025, equity awards outstanding under the 2023 plan cover 1,971,472 shares with a weighted‑average exercise price of $15.96, with 354,497 shares remaining available for issuance.
Pelthos Therapeutics Inc. reported its first substantial commercial period with Q2 2026 revenue of $15.6 million and six‑month 2026 revenue of $26.5 million, driven primarily by Zelsuvmi and initial license and collaboration revenue. There was no revenue in the comparable 2025 periods.
Operating scale-up and financing costs led to a Q2 2026 net loss of $23.4 million and a six‑month 2026 net loss of $48.5 million, versus $3.4 million and $5.4 million losses a year earlier. Cash and cash equivalents were $24.2 million at June 30, 2026, with net cash used in operations of $20.8 million in the first half. The balance sheet shows total liabilities of $138.9 million, including $43.3 million of related‑party convertible notes and a $26.6 million venture loan, resulting in a stockholders’ deficit of $1.5 million. Management states it sees sufficient liquidity, including an undrawn portion of a $50 million venture loan facility, to fund operations for at least twelve months.
Pelthos restated its March 31, 2026 quarter to revise Level 3 fair value measurements for convertible debt. The company highlights strong quarter‑over‑quarter growth in Zelsuvmi net product revenue since launch and continues amortizing significant acquired intangibles related to Zelsuvmi, Xepi and Xeglyze.
Pelthos Therapeutics Inc. reported strong top-line growth for the quarter ended June 30, 2026, driven by its lead dermatology product Zelsuvmi. Zelsuvmi net product revenue was $15.4 million in the second quarter, up 45% from $10.7 million in the first quarter, with 11,925 units dispensed by 4,571 prescribers and more than 25,000 patients treated since launch.
Total revenue reached $15.6 million for the quarter and $26.5 million for the first half of 2026. However, Pelthos remains unprofitable, posting a second-quarter net loss of $(23.4) million and first-half net loss of $(48.5) million, with Adjusted EBITDA of $(5.7) million improving from $(8.0) million in the prior quarter. Selling, general and administrative expenses rose to $27.7 million, including $5.3 million of non-recurring sales-based milestones and higher royalties.
Cash and cash equivalents were $24.2 million as of June 30, 2026, supported by a $50.0 million senior secured term loan facility with $30.0 million drawn and potential access to an additional $10.0 million, subject to lender discretion. The balance sheet showed total assets of $137.4 million, total liabilities of $138.9 million, and stockholders’ deficit of $(1.5) million. Pelthos highlighted future launches of Xepi in the first quarter of 2027 and Xeglyze in the third quarter of 2027 and noted that previously issued financial statements for the quarter ended March 31, 2026 will be restated.
Pelthos Therapeutics Inc. restated its quarter ended March 31, 2026 to correct a misapplication of ASC 820 in valuing Level 3 convertible debt. The fair value of convertible debt increased by $15.8 million to $39.1 million, raising total liabilities to $126.1 million and reducing stockholders’ equity to $19.3 million.
The change turned a previously reported gain on the debt into a $9.6 million loss and increased net loss for the quarter by $14.8 million to $25.1 million (basic and diluted loss per share $7.57). Comprehensive loss was $22.9 million. The restatement did not affect cash flows.
Management concluded a material weakness in internal control over financial reporting related to accounting for convertible debt existed as of March 31, 2026 and continues. Cash and cash equivalents were $32.0 million and working capital $44.8 million, and the company cites product revenues, a November 2025 convertible note and a January 2026 $50 million venture loan facility (of which $30 million was drawn) in concluding there is no substantial doubt about its ability to continue as a going concern for at least 12 months.
Pelthos Therapeutics Inc. determined that its condensed consolidated financial statements for the quarter ended March 31, 2026 can no longer be relied upon due to a misapplication of ASC 820 in valuing Level 3 fair value measurements of its convertible debt. After reassessing the valuation methods and inputs during the June 30, 2026 fair value measurement, the company concluded a restatement of that interim period is required.
The restatement will increase the fair value of convertible debt liabilities by $15.8 million, reduce accumulated other comprehensive income by $1.0 million, and increase accumulated deficit by $14.8 million. It will also add $14.8 million of non-cash expense to other expense and reduce other comprehensive loss by $1.0 million related to instrument credit risk. These changes affect net loss and loss per share but do not affect liquidity, cash, revenues, operating expenses, or operating loss.
The company identified a material weakness in internal control over financial reporting as of March 31, 2026, relating to controls over Level 3 fair value measurements of convertible debt and the Convertible Notes Subordination Agreement provisions. Disclosure controls and procedures were not effective, and Pelthos plans to outline remediation steps in an amended Q1 2026 report and its Q2 2026 report.